Vest Financial LLC Has $1.60 Million Stock Holdings in Pfizer Inc. $PFE

Vest Financial LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 39.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 65,904 shares of the biopharmaceutical company's stock after buying an additional 18,652 shares during the quarter. Vest Financial LLC's holdings in Pfizer were worth $1,598,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Capital Advisory Group Advisory Services LLC lifted its holdings in Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock worth $328,000 after buying an additional 388 shares in the last quarter. Citizens National Bank Trust Department lifted its stake in shares of Pfizer by 0.9% in the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company's stock valued at $1,118,000 after purchasing an additional 395 shares during the period. Trust Co of the South lifted its stake in shares of Pfizer by 1.5% in the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock valued at $712,000 after purchasing an additional 441 shares during the period. Charter Oak Capital Management LLC lifted its stake in shares of Pfizer by 4.3% in the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock valued at $258,000 after purchasing an additional 444 shares during the period. Finally, Ballentine Partners LLC lifted its stake in shares of Pfizer by 0.5% in the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company's stock valued at $2,260,000 after purchasing an additional 458 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of analyst reports. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday, October 8th. UBS Group reissued a "neutral" rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Morgan Stanley cut their price target on Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Friday. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Finally, Wall Street Zen downgraded Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $28.35.

Pfizer Price Performance

PFE stock opened at $24.53 on Wednesday. The stock has a 50-day moving average price of $24.88 and a two-hundred day moving average price of $24.12. The stock has a market cap of $139.44 billion, a PE ratio of 13.05, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.82.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer's dividend payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.